| Activatable autophagy inhibition-primed chemodynamic therapy via targeted sandwich-like two-dimensional nanosheets H Wu, F Wu, T Zhou, Z Hu, W Wang, X Liang, J Wang, C You, B Sun, F Lin Chemical Engineering Journal 431, 133470, 2022 | 20 | 2022 |
| Treatment strategies for metastatic gastric cancer: chemotherapy, palliative surgery or radiotherapy? X Liang, J Zhu, Y Li, Y Xu, K Chen, L Lv, W Mao Future Oncology, 2019 | 20 | 2019 |
| Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer L Lv, X Liang, D Wu, F Wang, Y Zhang, H Cang, X Deng, M Li Journal of Cancer 12 (8), 2385, 2021 | 19 | 2021 |
| Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors Y Cui, P Zhang, X Liang, J Xu, X Liu, Y Wu, J Zhang, W Wang, F Zhang, ... American Journal of Cancer Research 12 (4), 1766, 2022 | 18 | 2022 |
| Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study J Zhu, X Liang, D Wu, S Chen, B Yang, W Mao, D Shen Medicine 100 (15), e25237, 2021 | 17 | 2021 |
| A pan-cancer study of KMT2 family as therapeutic targets in cancer J Zhu, Z Liu, X Liang, L Wang, D Wu, W Mao, D Shen Journal of Oncology 2022, 2022 | 7 | 2022 |
| PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers J Dai, Y Cui, X Liang, J Xu, J Li, Y Chen, E Zhang, R Guo Frontiers in Genetics 13, 1066347, 2023 | 6 | 2023 |
| Bone metastasis in esophageal adenocarcinoma and squamous cell carcinoma: a SEER-based study Y Qin, J Mao, X Liang, N Wang, M Yuan, J Zhu, D Wu, Q Wang General Thoracic and Cardiovascular Surgery 70 (5), 479-490, 2022 | 6 | 2022 |
| Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes Q Wang, J Li, J Zhu, J Mao, C Duan, X Liang, L Zhu, M Zhu, Z Zhang, ... Clinical and Translational Medicine 12 (6), e882, 2022 | 5 | 2022 |
| Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Y Cui, X Liu, Y Wu, X Liang, J Dai, Z Zhang, R Guo Frontiers in Oncology 12, 798401, 2022 | 5 | 2022 |
| Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC X Liang, W Zhang, J Li, J Zhu, J Shao, J Wang, H Wu, J Dai, J Li, J Xu, ... Journal of Cancer Research and Clinical Oncology 149 (3), 1211-1220, 2023 | 4 | 2023 |
| Pyroptosis: a double-edged sword in lung cancer and other respiratory diseases X Liang, Y Qin, D Wu, Q Wang, H Wu Cell Communication and Signaling 22 (1), 40, 2024 | 1 | 2024 |
| Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients Y Chen, N Jiang, X Liang, N Chen, Y Chen, C Zhang, J Shi, R Guo Oncology Letters 26 (2), 1-11, 2023 | 1 | 2023 |
| Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer Y Qin, X Liang, H Wu, X Sun, S Yan, N Wang, M Yuan, Q Wang, D Wu Angiology, 00033197231213197, 2023 | | 2023 |
| Endoscopic therapy versus esophagectomy for T1bN0M0 esophageal cancer: A population-based study using propensity score matching J Zhu, X Liang, S Chen, Y Qin, D Shen, X Yang Heliyon 9 (11), 2023 | | 2023 |
| A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network X Liang, R Guan, J Zhu, Y Meng, J Zhu, Y Yang, Y Cui, J Dai, W Mao, L Lv, ... Journal of Cancer Research and Clinical Oncology 149 (13), 12265-12274, 2023 | | 2023 |
| Venous and Arterial Thromboembolism in Patients with Metastatic Lung Cancer Y Qin, L Zhang, X Liang, X Sun, N Wang, M Yuan, Q Wang, D Wu Clinical and Applied Thrombosis/Hemostasis 29, 10760296231159121, 2023 | | 2023 |
